Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Financial Disclosure by Clinical Investigators, 30146 [E6-7987]
Download as PDF
30146
Federal Register / Vol. 71, No. 101 / Thursday, May 25, 2006 / Notices
Dated: May 18, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6–7985 Filed 5–24–06; 8:45 am]
approval expires on April 30, 2009. A
copy of the supporting statement for this
information collection is available on
the Internet at https://www.fda.gov/
ohrms/dockets.
BILLING CODE 4160–01–S
Dated: May 18, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6–7987 Filed 5–24–06; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
BILLING CODE 4160–01–S
[Docket No. 2005N–0296]
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Financial Disclosure by Clinical
Investigators
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a collection of information entitled
‘‘Financial Disclosure by Clinical
Investigators’’ has been approved by the
Office of Management and Budget
(OMB) under the Paperwork Reduction
Act of 1995.
FOR FURTHER INFORMATION CONTACT:
Karen L. Nelson, Office of Management
Programs (HFA–250), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–1482.
SUPPLEMENTARY INFORMATION: In the
Federal Register of February 10, 2006
(71 FR 7051), the agency announced
that the proposed information collection
had been submitted to OMB for review
and clearance under 44 U.S.C. 3507. An
agency may not conduct or sponsor, and
a person is not required to respond to,
a collection of information unless it
displays a currently valid OMB control
number. OMB has now approved the
information collection and has assigned
OMB control number 0910–0396. The
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005N–0500]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Requirements for
Collection of Data Relating to the
Prevention of Medical Gas Mixups at
Health Care Facilities—Survey
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by June 26,
2006.
ADDRESSES: OMB is still experiencing
significant delays in the regular mail,
including first class and express mail,
and messenger deliveries are not being
accepted. To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: Fumie Yokota, Desk Officer
for FDA, FAX: 202–395–6974.
FOR FURTHER INFORMATION CONTACT:
Karen Nelson, Office of Management
Programs (HFA–250), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–1482.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
Requirements for Collection of Data
Relating to the Prevention of Medical
Gas Mixups at Healthcare Facilities—
Survey (OMB Control Number 0910–
0548)—Extension
FDA has received four reports of
medical gas mixups occurring during
the past 7 years. These reports were
received from hospitals and nursing
homes and involved 7 deaths and 15
injuries to patients who were thought to
be receiving medical grade oxygen, but
who were actually receiving a different
gas (e.g., nitrogen, argon) that had been
mistakenly connected to the facility’s
oxygen supply system. In 2001, FDA
published guidance making
recommendations to help hospitals,
nursing homes, and other health care
facilities avoid the tragedies that result
from medical gas mixups and alerting
these facilities to the hazards. This
survey is intended to assess the degree
of facilities’ compliance with safety
measures to prevent mixups and to
determine if further steps are warranted
to ensure the safety of patients.
In the Federal Register of January 3,
2006 (71 FR 122), FDA published a 60day notice requesting public comment
on the information collection
provisions. No comments were received.
FDA estimates the burden of this
collection of information as follows:
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
21 CFR Section
No. of Respondents
210 and 211
Total
cchase on PROD1PC60 with NOTICES
1There
Annual Frequency
per Response
285
285
Total Annual Responses
1
1
285
285
Hours per Response
.25
.25
71.25
71.25
are no capital costs or operating and maintenance costs associated with this collection of information.
VerDate Aug<31>2005
16:42 May 24, 2006
Jkt 208001
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
E:\FR\FM\25MYN1.SGM
Total Hours
25MYN1
Agencies
[Federal Register Volume 71, Number 101 (Thursday, May 25, 2006)]
[Notices]
[Page 30146]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-7987]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005N-0296]
Agency Information Collection Activities; Announcement of Office
of Management and Budget Approval; Financial Disclosure by Clinical
Investigators
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
collection of information entitled ``Financial Disclosure by Clinical
Investigators'' has been approved by the Office of Management and
Budget (OMB) under the Paperwork Reduction Act of 1995.
FOR FURTHER INFORMATION CONTACT: Karen L. Nelson, Office of Management
Programs (HFA-250), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-827-1482.
SUPPLEMENTARY INFORMATION: In the Federal Register of February 10, 2006
(71 FR 7051), the agency announced that the proposed information
collection had been submitted to OMB for review and clearance under 44
U.S.C. 3507. An agency may not conduct or sponsor, and a person is not
required to respond to, a collection of information unless it displays
a currently valid OMB control number. OMB has now approved the
information collection and has assigned OMB control number 0910-0396.
The approval expires on April 30, 2009. A copy of the supporting
statement for this information collection is available on the Internet
at https://www.fda.gov/ohrms/dockets.
Dated: May 18, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6-7987 Filed 5-24-06; 8:45 am]
BILLING CODE 4160-01-S